842136-58-7

Usage

Uses

Used in Pharmaceutical Research:
6-FLUOROPYRIDINE-2-BORONIC ACID PINACOL ESTER is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its reactivity and stability make it a valuable building block for the development of novel drugs with improved therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 6-FLUOROPYRIDINE-2-BORONIC ACID PINACOL ESTER is used as a versatile reagent for the formation of carbon-carbon and carbon-heteroatom bonds. Its unique properties allow for the creation of complex organic compounds with potential applications in various industries.
Used in Medicinal Chemistry:
6-FLUOROPYRIDINE-2-BORONIC ACID PINACOL ESTER is employed as a structural component in the design of bioactive molecules. Its fluoropyridine group can be utilized to enhance the pharmacological properties of these molecules, leading to the development of more effective therapeutic agents.
Used in Chemical Research:
In the realm of chemical research, 6-FLUOROPYRIDINE-2-BORONIC ACID PINACOL ESTER serves as a valuable tool for studying the properties and reactions of boronic acid derivatives. Its unique characteristics provide insights into the behavior of similar compounds and contribute to the understanding of organic and inorganic chemistry.
Used in Drug Development:
6-FLUOROPYRIDINE-2-BORONIC ACID PINACOL ESTER is utilized in the development of new drugs with improved efficacy and selectivity. Its incorporation into drug candidates can lead to the discovery of novel therapeutic agents with the potential to treat various diseases and conditions.
Used in Chemical Industry:
In the chemical industry, 6-FLUOROPYRIDINE-2-BORONIC ACID PINACOL ESTER is employed as a raw material for the production of various organic compounds. Its versatility and reactivity make it a valuable component in the synthesis of specialty chemicals and intermediates for a wide range of applications.

InChI:InChI=1/C11H15BFNO2/c1-10(2)11(3,4)16-12(15-10)8-6-5-7-9(13)14-8/h5-7H,1-4H3

Upstream product

• 144100-07-2 2-bromo-6-fluoropyridine 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1401348-75-1 5-(3-(6-fluoropyridin-2-yl)-1-tosyl-1H-indol-5-yl)-N-(4-methoxybenzyl)-1,3,4-thiadiazol-2-amine 
• 1401349-03-8 4-(6-(5-(5-(4-methoxybenzylamino)-1,3,4-thiadiazol-2-yl)-1H-indol-3-yl)pyridin-2-yl)-1-methylpiperazin-2-one 
• 1401349-02-7 4-(6-(5-(5-(4-methoxybenzylamino)-1,3,4-thiadiazol-2-yl)-1-tosyl-1H-indol-3-yl)pyridin-2-yl)-1-methylpiperazin-2-one 
• 1401348-76-2 5-(3-(6-fluoropyridin-2-yl)-1-tosyl-1H-indol-5-yl)-1,3,4-thiadiazol-2-amine 
• 1270077-79-6 (R)-3-[5'-chloro-6-(cyclohexylmethylamino)-[2,4,]bipyridinyl-2'-ylcarbamoyl]piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain

The design, synthesis, and biological evaluation of novel 3-aryl-indazole derivatives as peripherally selective pan-Trk inhibitors are described. Three strategies were used to obtain a potent compound exhibiting low central nervous system (CNS) penetratio

P2X7 MODULATORS

The present invention is directed to a compound of Formula (I) The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)

N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES

The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.

N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a compound of the general formula (1): wherein one of X and Y is N and the other is an optionally substituted carbon atom, and Z2-Z5 represent one or two nitrogen atoms, as further described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals and as components of pharmaceutical compositions. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds described herein or pharmaceutical compositions comprising such compounds.

Spiro Compounds As NPY Y5 Receptor Antagonists

The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R is an aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano;Z1 is H, C1-C4 alkyl or F;Z is CH2, CH(C1-C4 alkyl), C(C1-C4 alkyl)2 or a bond;A is a 6-10 membered aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or —C(═O)—X; or —O(CH2)0-1R1;B is hydrogen or is a 5-6 membered heteroaryl, or a 4-6 membered heterocycle, or phenyl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, hydroxyl, cyano; A and B being linked via any atom;R1 is —(C1-C4)alkyl(C1-C4)alkoxy; or C3-C8 cycloalkyl; or R1 is an aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or R1 is a 4-6 membered heterocycle, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano;X is OR2 or NR3R4;R2 is C1-C4 alkyl;R3 is hydrogen or together with R4 and the nitrogen form a 5-6 saturated membered ring;R4 is C3-C8 cycloalkyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY Y5 receptor antagonists and as agents for the treatment and/or prophylaxis of eating disorders such as a binge eating disorder.